Genmab

1.350

DKK

+0,22 %

Mindre end 1K følgere

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

+0,22%

-3,5%

-10,39%

-9,55%

-15,28%

-30,93%

-45,8%

-17,93%

+3.858,94%

Genmab er et farmaceutisk selskab. Virksomheden har specialiseret sig i forskning og udvikling af antistoffer, som hovedsageligt bruges til behandling af kræftpatienter med lymfatisk leukæmi og solide tumorer. Forskning og udvikling er baseret på virksomhedens egen udviklede tekniske platform, og driften foregår på globalt plan. Genmab blev grundlagt i 1999 og har sit hovedkontor med beliggenhed i København.

Markedsværdi

86,56 mia. DKK

Aktieomsætning

140,32 mio. DKK

Omsætning

21,53 mia.

EBIT %

31,14 %

P/E

11,05

Udbytteafkast, %

-

Finanskalender

8.5

2025

Delårsrapport Q1'25

7.8

2025

Delårsrapport Q2'25

6.11

2025

Delårsrapport Q3'25

Alle

Analyse

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelsefor 3 timer siden

Transactions in Connection with Share Buy-back Program

Selskabsmeddelelse22.4.2025, 11.23

Transactions in Connection with Share Buy-back Program

Selskabsmeddelelse15.4.2025, 10.21

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Selskabsmeddelelse14.4.2025, 12.42

Transactions in Connection with Share Buy-back Program

Selskabsmeddelelse10.4.2025, 16.20

Genmab A/S Share Capital Reduction

Selskabsmeddelelse7.4.2025, 11.42

Transactions In Connection with Share Buy-back Program

Selskabsmeddelelse1.4.2025, 19.53

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Pressemeddelelse31.3.2025, 15.20

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Selskabsmeddelelse31.3.2025, 12.18

Transactions in connection with share buy-back program

Pressemeddelelse27.3.2025, 12.00

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Selskabsmeddelelse25.3.2025, 21.28

Genmab Announces Initiation of Share Buy-Back Program

Selskabsmeddelelse22.3.2025, 03.28

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Pressemeddelelse17.3.2025, 16.19

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Selskabsmeddelelse12.3.2025, 18.19

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Selskabsmeddelelse12.3.2025, 18.13

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Selskabsmeddelelse10.3.2025, 14.13

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Selskabsmeddelelse4.3.2025, 16.57

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Selskabsmeddelelse28.2.2025, 21.04

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Selskabsmeddelelse28.2.2025, 21.00

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Selskabsmeddelelse25.2.2025, 19.30

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.